【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低利好药明系

金吾财讯12-09

金吾财讯 | 摩根士丹利称，美国2025财年国防授权法案(NDAA)没有生物安全法案或任何药明系的名字，这对药明系和其他具有重大海外收入敞口的中国CRO（合同研究组织）/CDMO（合同研发生产组织）公司是一个积极的进展。

投行Jefferies也在报告中称，进展超出投资者预期，考虑到估值吸引力和投资者的低仓位，现在是重新审视中国CDMO公司的关键节点。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490648887?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg","is_english":false,"pubTime":"2024-12-09 08:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490648887","market":"nz","top_or_hot":-1,"title":"【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低 利好药明系","media":"金吾财讯","content":"<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>称，美国2025财年国防授权法案(NDAA)没有生物安全法案或任何药明系的名字，这对药明系和其他具有重大海外收入敞口的中国CRO（合同研究组织）/CDMO（合同研发生产组织）公司是一个积极的进展。</p><p>投行Jefferies也在报告中称，进展超出投资者预期，考虑到估值吸引力和投资者的低仓位，现在是重新审视中国CDMO公司的关键节点。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低 利好药明系</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低 利好药明系\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 08:55 北京时间&nbsp;&nbsp;&nbsp;<a href=1949185><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 摩根士丹利称，美国2025财年国防授权法案(NDAA)没有生物安全法案或任何药明系的名字，这对药明系和其他具有重大海外收入敞口的中国CRO（合同研究组织）/CDMO（合同研发生产组织）公司是一个积极的进展。投行Jefferies也在报告中称，进展超出投资者预期，考虑到估值吸引力和投资者的低仓位，现在是重新审视中国CDMO公司的关键节点。</p>\n\n<a href=\"1949185\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"1949185","article_id":"2490648887","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490648887","pubTimestamp":1733705759,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 摩根士丹利称，美国2025财年国防授权法案(NDAA)没有生物安全法案或任何药明系的名字，这对药明系和其他具有重大海外收入敞口的中国CRO（合同研究组织）/CDMO（合同研发生产组织）公司是一个积极的进展。投行Jefferies也在报告中称，进展超出投资者预期，考虑到估值吸引力和投资者的低仓位，现在是重新审视中国CDMO公司的关键节点。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","BK1141":"生命科学工具和服务","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","MS":"摩根士丹利","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","BK1583":"高瓴概念","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0051755006.USD":"摩根大通中国A (dist)","02359":"药明康德","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK4504":"桥水持仓","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","02268":"药明合联","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","02269":"药明生物","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0971096721.USD":"富达环球金融服务 A","LU0052750758.USD":"富兰克林中国基金A Acc"},"translate_title":"[Brokerage Focus] Morgan Stanley says the possibility of the U.S. biosafety bill being passed within the year is greatly reduced, benefiting WuXi","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MS":1,"02269":0.9,"02359":0.9,"02268":0.9},"content_text":"金吾财讯 | 摩根士丹利称，美国2025财年国防授权法案(NDAA)没有生物安全法案或任何药明系的名字，这对药明系和其他具有重大海外收入敞口的中国CRO（合同研究组织）/CDMO（合同研发生产组织）公司是一个积极的进展。投行Jefferies也在报告中称，进展超出投资者预期，考虑到估值吸引力和投资者的低仓位，现在是重新审视中国CDMO公司的关键节点。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490648887"}

【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低 利好药明系

精彩评论

【券商聚焦】摩根士丹利称美国生物安全法案年内通过的可能性大大降低利好药明系